Drugs / ONC-PluReceptor NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07283679 | Feb 2026 → Sep 2031 expected | B-cell non-Hodgkin lymphoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONC-PluReceptor NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07283679 ↗ |
| Modality | Cell therapy | “ONC-PluReceptor NK cell therapy” NCT07283679 ↗ |